Victoria Louise Reid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Victoria Louise Reid has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Amara Callistus Nwosu
Lancaster Medical School, Lancaster University, Lancaster, UK
3 shared publications Chris Probert
Department of Gastroenterology, University of Liverpool, Liverpool, United Kingdom
2 shared publicationsJohn E Ellershaw
The Marie Curie Palliative Care Institute Liverpool, University of Liverpool, Liverpool, United Kingdom
2 shared publicationsN.R. Webster
Institute of Medical Sciences Banaras Hindu University
2 shared publicationsRachael McDonald
Renal Medicine, Aintree University Hospital NHS Foundation Trust, Liverpool, United Kingdom
2 shared publicationsA.M. Almawash
1 shared publication
Latest Publications
- Open Access
- 6 April 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (4) , e0175123
A systematically structured review of biomarkers of dying in cancer patients in the last months of life; An exploration of the biology of dying
The Neuberger review made a number of recommendations to improve end of life care, including research into the biology of dying. An important aspect of the biology of dying is the identification of biomarkers as indices of disease processes. Biomarkers have the potential to inform the current, limited understanding of the dying process and assist clinicians in recognising dying, in particular how to distinguish dying from reversible acute deterioration. To critically appraise the literature on biological factors that may be used as prognostic indicators in advanced cancer patients and to identify candidate biomarkers of the dying process that can be measured serially in cancer patients’ bodily fluids. A systematically structured review was conducted using three electronic databases. A hand search of six peer-reviewed journals and conference abstracts was also conducted. Studies reporting prognostic biomarkers in cancer patients with a median survival of ≤90 days and post-mortem studies were included. Final levels of evidence and recommendations were made using the Evidence Based Medicine modified GRADE system. 30 articles were included. Seven prognostic biological factors demonstrated Grade A evidence (lymphocyte count, white blood cell count, serum C-reactive protein, albumin, sodium, urea and alkaline phosphatase). An additional eleven prognostic factors were identified with Grade B evidence (platelet count, international normalised ratio, serum vitamin B12, prealbumin, bilirubin, cholesterol, aspartate aminotransferase, alanine transaminase, lactate dehydrogenase, pseudocholinesterase and urate). A number of biomarkers were specifically identified in the last two weeks of life but limitations exist. No post-mortem studies met the inclusion criteria. The biology of dying is an important area for future research, with the evidence focused on signs, symptoms and prognostic factors. This review identifies a number of common themes shared amongst advanced cancer patients and highlights candidate biomarkers which may be indicative of a common biological process to dying.
- 6 April 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (4) , e0175123
Open AccessA systematically structured review of biomarkers of dying in cancer patients in the last months of life; An exploration of the biology of dying
The Neuberger review made a number of recommendations to improve end of life care, including research into the biology of dying. An important aspect of the biology of dying is the identification of biomarkers as indices of disease processes. Biomarkers have the potential to inform the current, limited understanding of the dying process and assist clinicians in recognising dying, in particular how to distinguish dying from reversible acute deterioration. To critically appraise the literature on biological factors that may be used as prognostic indicators in advanced cancer patients and to identify candidate biomarkers of the dying process that can be measured serially in cancer patients’ bodily fluids. A systematically structured review was conducted using three electronic databases. A hand search of six peer-reviewed journals and conference abstracts was also conducted. Studies reporting prognostic biomarkers in cancer patients with a median survival of ≤90 days and post-mortem studies were included. Final levels of evidence and recommendations were made using the Evidence Based Medicine modified GRADE system. 30 articles were included. Seven prognostic biological factors demonstrated Grade A evidence (lymphocyte count, white blood cell count, serum C-reactive protein, albumin, sodium, urea and alkaline phosphatase). An additional eleven prognostic factors were identified with Grade B evidence (platelet count, international normalised ratio, serum vitamin B12, prealbumin, bilirubin, cholesterol, aspartate aminotransferase, alanine transaminase, lactate dehydrogenase, pseudocholinesterase and urate). A number of biomarkers were specifically identified in the last two weeks of life but limitations exist. No post-mortem studies met the inclusion criteria. The biology of dying is an important area for future research, with the evidence focused on signs, symptoms and prognostic factors. This review identifies a number of common themes shared amongst advanced cancer patients and highlights candidate biomarkers which may be indicative of a common biological process to dying.
- Open Access
- 1 March 2017
- Published by BMJ
- Vol. 7 (Suppl 1) , A2.2-A2
O-5 A systematically structured review on biomarkers of dying in cancer patients at the end of life; an exploration of potential mechanisms for the biology of dying
Background The Neuberger review made a number recommendation to improve end of life care, including research into the biology of dying. An important aspect of the biology of dying is the identification of biomarkers of the dying process. Biomarkers have the potential to assist clinicians in recognising dying, in particular how to distinguish dying from reversible acute deterioration. Objectives To critically appraise the existing literature on prognostic biological factors that impact survival in advanced cancer patients in the last days, weeks or months of life; to identify prognostic models for advanced cancer patients, which could assist clinicians to prognosticate in the last days, weeks or months of life; and to identify candidate biomarkers of the dying process that can be measured serially in bodily fluids. Methods A systematically structured review was conducted using three electronic databases. A hand search of six peer-reviewed journals and conference abstracts was also conducted. Studies reporting biomarkers of dying in cancer patients with a median survival of ≤90 days, and post-mortem studies were included. Results 30 articles were included. There is grade A evidence for the following biological factors: serum CRP, WBC count, lymphopaenia, serum sodium, urea, ALP and hypoalbuminaemia. An additional nine prognostic factors were identified with grade B evidence including: thrombocytopaenia, elevated vitamin B12, hyperbilirubinaemia, hypocholesterolaemia, elevated AST, ALT, LDH and INR. In the last two weeks of life, a number of biomarkers have been identified but limitations exist. No post-mortem studies met the inclusion criteria. Conclusion The biology of dying is an important area for future research interest. The evidence base to date is largely focused on symptoms, signs and prognostic factors. We identify a number common themes shared amongst advanced cancer patients, candidate biomarkers of dying, and areas for future research including non-invasive research methodologies.
- 1 March 2017
- Published by BMJ
- Vol. 7 (Suppl 1) , A2.2-A2
Open AccessO-5 A systematically structured review on biomarkers of dying in cancer patients at the end of life; an exploration of potential mechanisms for the biology of dying
Background The Neuberger review made a number recommendation to improve end of life care, including research into the biology of dying. An important aspect of the biology of dying is the identification of biomarkers of the dying process. Biomarkers have the potential to assist clinicians in recognising dying, in particular how to distinguish dying from reversible acute deterioration. Objectives To critically appraise the existing literature on prognostic biological factors that impact survival in advanced cancer patients in the last days, weeks or months of life; to identify prognostic models for advanced cancer patients, which could assist clinicians to prognosticate in the last days, weeks or months of life; and to identify candidate biomarkers of the dying process that can be measured serially in bodily fluids. Methods A systematically structured review was conducted using three electronic databases. A hand search of six peer-reviewed journals and conference abstracts was also conducted. Studies reporting biomarkers of dying in cancer patients with a median survival of ≤90 days, and post-mortem studies were included. Results 30 articles were included. There is grade A evidence for the following biological factors: serum CRP, WBC count, lymphopaenia, serum sodium, urea, ALP and hypoalbuminaemia. An additional nine prognostic factors were identified with grade B evidence including: thrombocytopaenia, elevated vitamin B12, hyperbilirubinaemia, hypocholesterolaemia, elevated AST, ALT, LDH and INR. In the last two weeks of life, a number of biomarkers have been identified but limitations exist. No post-mortem studies met the inclusion criteria. Conclusion The biology of dying is an important area for future research interest. The evidence base to date is largely focused on symptoms, signs and prognostic factors. We identify a number common themes shared amongst advanced cancer patients, candidate biomarkers of dying, and areas for future research including non-invasive research methodologies.
- Open Access
- 31 August 2016
- Published by BMJ in BMJ Supportive & Palliative Care
- Vol. 7 (2) , 212-217
Use of podcast technology to facilitate education, communication and dissemination in palliative care: the development of the AmiPal podcast
Objectives Podcasts have the potential to facilitate communication about palliative care with researchers, policymakers and the public. Some podcasts about palliative care are available; however, this is not reflected in the academic literature. Further study is needed to evaluate the utility of podcasts to facilitate knowledge-transfer about subjects related to palliative care. The aims of this paper are to (1) describe the development of a palliative care podcast according to international recommendations for podcast quality and (2) conduct an analysis of podcast listenership over a 14-month period. Methods The podcast was designed according to internationally agreed quality indicators for medical education podcasts. The podcast was published on SoundCloud and was promoted via social media. Data were analysed for frequency of plays and geographical location between January 2015 and February 2016. Results 20 podcasts were developed which were listened to 3036 times (an average of 217 monthly plays). The Rich Site Summary feed was the most popular way to access the podcast (n=1937; 64%). The mean duration of each podcast was 10 min (range 3–21 min). The podcast was listened to in 68 different countries and was most popular in English-speaking areas, of which the USA (n=1372, 45.2%), UK (n=661, 21.8%) and Canada (n=221, 7.3%) were most common. Conclusions A palliative care podcast is a method to facilitate palliative care discussion with global audience. Podcasts offer the potential to develop educational content and promote research dissemination. Future work should focus on content development, quality metrics and impact analysis, as this form of digital communication is likely to increase and engage wider society.
- 31 August 2016
- Published by BMJ in BMJ Supportive & Palliative Care
- Vol. 7 (2) , 212-217
Open AccessUse of podcast technology to facilitate education, communication and dissemination in palliative care: the development of the AmiPal podcast
Objectives Podcasts have the potential to facilitate communication about palliative care with researchers, policymakers and the public. Some podcasts about palliative care are available; however, this is not reflected in the academic literature. Further study is needed to evaluate the utility of podcasts to facilitate knowledge-transfer about subjects related to palliative care. The aims of this paper are to (1) describe the development of a palliative care podcast according to international recommendations for podcast quality and (2) conduct an analysis of podcast listenership over a 14-month period. Methods The podcast was designed according to internationally agreed quality indicators for medical education podcasts. The podcast was published on SoundCloud and was promoted via social media. Data were analysed for frequency of plays and geographical location between January 2015 and February 2016. Results 20 podcasts were developed which were listened to 3036 times (an average of 217 monthly plays). The Rich Site Summary feed was the most popular way to access the podcast (n=1937; 64%). The mean duration of each podcast was 10 min (range 3–21 min). The podcast was listened to in 68 different countries and was most popular in English-speaking areas, of which the USA (n=1372, 45.2%), UK (n=661, 21.8%) and Canada (n=221, 7.3%) were most common. Conclusions A palliative care podcast is a method to facilitate palliative care discussion with global audience. Podcasts offer the potential to develop educational content and promote research dissemination. Future work should focus on content development, quality metrics and impact analysis, as this form of digital communication is likely to increase and engage wider society.
- 4 September 2013
- Published by BMJ in BMJ Case Reports
- Vol. 2013
Rapid recovery of membrane cofactor protein (MCP; CD46) associated atypical haemolytic uraemic syndrome with plasma exchange
Atypical haemolytic uraemic syndrome (aHUS), unlike typical HUS is due to complement dysregulation. At least one abnormality of the complement system can be identified in 70% of patients. aHUS is associated with a poor prognosis with 25% mortality and 50% progress to end-stage renal disease. Genetic abnormalities in the complement system, proteins including CFH, CFI, CFB, C3, CFHR1/3 and MCP (CD46) lead to uncontrolled complement activation in aHUS. We presented the second reported case of aHUS associated with a heterozygous c.191G > T mutation in exon 2 of MCP who responded rapidly to plasma exchange.
- 4 September 2013
- Published by BMJ in BMJ Case Reports
- Vol. 2013
Rapid recovery of membrane cofactor protein (MCP; CD46) associated atypical haemolytic uraemic syndrome with plasma exchange
Atypical haemolytic uraemic syndrome (aHUS), unlike typical HUS is due to complement dysregulation. At least one abnormality of the complement system can be identified in 70% of patients. aHUS is associated with a poor prognosis with 25% mortality and 50% progress to end-stage renal disease. Genetic abnormalities in the complement system, proteins including CFH, CFI, CFB, C3, CFHR1/3 and MCP (CD46) lead to uncontrolled complement activation in aHUS. We presented the second reported case of aHUS associated with a heterozygous c.191G > T mutation in exon 2 of MCP who responded rapidly to plasma exchange.
- Open Access
- 4 January 2013
- Published by BMJ in BMJ Case Reports
- Vol. 2013
Symmetrical peripheral gangrene and disseminated intravascular coagulation associated with pelvi-ureteric junction obstruction
Despite treatment the patient deteriorated with abdominal tenderness, refractory hypoglycaemia, mucocutaneous bleeding, symmetric areas of petechiae, ecchymotic plaques and dry gangrene of the upper and lower extremities (figures 1 and 2). Laboratory investigations suggested disseminated intravascular coagulation (DIC) (platelets 13×109/l, PT 23.3 s, APTT 68.5 s and normal fibrinogen). A vasculitis screen was negative. She was treated with intravenous tazocin, hydrocortisone and platelets. On day 7, CT imaging demonstrated left pelvi-ureteric junction (PUJ) obstruction, rupture of the left renal tract (figure 3) and multiple abdominal and pelvic fluid collections. A left-sided ureteric stent was inserted by the urologists, and the digits affected by dry gangrene were autoamputated under the plastic surgeons.
- 4 January 2013
- Published by BMJ in BMJ Case Reports
- Vol. 2013
Open AccessSymmetrical peripheral gangrene and disseminated intravascular coagulation associated with pelvi-ureteric junction obstruction
Despite treatment the patient deteriorated with abdominal tenderness, refractory hypoglycaemia, mucocutaneous bleeding, symmetric areas of petechiae, ecchymotic plaques and dry gangrene of the upper and lower extremities (figures 1 and 2). Laboratory investigations suggested disseminated intravascular coagulation (DIC) (platelets 13×109/l, PT 23.3 s, APTT 68.5 s and normal fibrinogen). A vasculitis screen was negative. She was treated with intravenous tazocin, hydrocortisone and platelets. On day 7, CT imaging demonstrated left pelvi-ureteric junction (PUJ) obstruction, rupture of the left renal tract (figure 3) and multiple abdominal and pelvic fluid collections. A left-sided ureteric stent was inserted by the urologists, and the digits affected by dry gangrene were autoamputated under the plastic surgeons.
- 1 October 2012
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 109 (4) , 503-513
Role of microparticles in sepsis
This review discusses the role of microparticles in inflammation, coagulation, vascular function, and most importantly, their physiological and pathological functions in sepsis. Microparticles are proinflammatory, procoagulant membrane vesicles released from various cell types. They are detectable in normal individuals and basal levels correlate with a balance between cell proliferation, stimulation, and destruction. Haemostatic imbalance leads to various pathological states of inflammation and thrombosis including cardiovascular disease and sepsis, where circulating microparticles display both an increase in number and phenotypic change. Microparticles, mainly of platelet origin enable both local and disseminated amplification of the haemostatic response to endothelial injury through exposure of phosphatidylserine, tissue factor, and coagulation factor binding sites. Surface expression of membrane antigens by microparticles facilitates cytoadhesion, chemotaxis, and cytokine secretion to drive a proinflammatory response. Microparticles behave as vectors in the transcellular exchange of biological information and are important regulators of endothelial function and angiogenesis. The extent to which circulating microparticles contribute to the pathogenesis of sepsis and disseminated intravascular coagulation is currently unknown. Microparticles may in fact be beneficial in early sepsis, given that activated protein C bound to endothelium-derived microparticles retains anticoagulant activity, and increased circulating microparticles are protective against vascular hyporeactivity. Elevated levels of microparticles in early sepsis may therefore compensate for the host's systemic inflammatory response. Importantly, in vivo, septic microparticles induce deleterious changes in the expression of enzyme systems related to inflammation and oxidative stress, thus they may represent important contributors to multi-organ failure in septic shock.
- 1 October 2012
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 109 (4) , 503-513
Role of microparticles in sepsis
This review discusses the role of microparticles in inflammation, coagulation, vascular function, and most importantly, their physiological and pathological functions in sepsis. Microparticles are proinflammatory, procoagulant membrane vesicles released from various cell types. They are detectable in normal individuals and basal levels correlate with a balance between cell proliferation, stimulation, and destruction. Haemostatic imbalance leads to various pathological states of inflammation and thrombosis including cardiovascular disease and sepsis, where circulating microparticles display both an increase in number and phenotypic change. Microparticles, mainly of platelet origin enable both local and disseminated amplification of the haemostatic response to endothelial injury through exposure of phosphatidylserine, tissue factor, and coagulation factor binding sites. Surface expression of membrane antigens by microparticles facilitates cytoadhesion, chemotaxis, and cytokine secretion to drive a proinflammatory response. Microparticles behave as vectors in the transcellular exchange of biological information and are important regulators of endothelial function and angiogenesis. The extent to which circulating microparticles contribute to the pathogenesis of sepsis and disseminated intravascular coagulation is currently unknown. Microparticles may in fact be beneficial in early sepsis, given that activated protein C bound to endothelium-derived microparticles retains anticoagulant activity, and increased circulating microparticles are protective against vascular hyporeactivity. Elevated levels of microparticles in early sepsis may therefore compensate for the host's systemic inflammatory response. Importantly, in vivo, septic microparticles induce deleterious changes in the expression of enzyme systems related to inflammation and oxidative stress, thus they may represent important contributors to multi-organ failure in septic shock.
- 1 January 2012
- Published by Wolters Kluwer Health in European Journal of Anaesthesiology
- Vol. 29 (1) , 57-59
Postoperative nausea and vomiting
- 1 January 2012
- Published by Wolters Kluwer Health in European Journal of Anaesthesiology
- Vol. 29 (1) , 57-59
Postoperative nausea and vomiting
- 1 August 2011
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 107 (2) , 193-201
Melatonin and structurally similar compounds have differing effects on inflammation and mitochondrial function in endothelial cells under conditions mimicking sepsis
Development of organ dysfunction associated with sepsis is due in part to oxidative damage to mitochondria. Melatonin regulates the sleep-wake cycle and also has potent antioxidant activity. The aim of this study was to determine the effects of melatonin and other structurally related compounds on mitochondrial function, endogenous glutathione (GSH), and control of cytokine expression under conditions mimicking sepsis. Human endothelial cells were treated with lipopolysaccharide (LPS) plus peptidoglycan G (PepG) to simulate sepsis, in the presence of melatonin, 6-hydroxymelatonin, tryptamine, or indole-3-carboxylic acid. Nuclear factor κB (NFκB) activation, interleukin (IL)-6 and IL-8, total glutathione, mitochondrial membrane potential, and metabolic activity were measured. LPS and PepG treatment resulted in elevated IL-6 and IL-8 levels preceded by activation of NFκB (all P<0.0001). Treatment with all four compounds resulted in lower IL-6 and IL-8 levels, and lower NFκB activation (P<0.0001). Loss of mitochondrial membrane potential and endogenous glutathione was seen when cells were exposed to LPS/PepG, but these were maintained in cells co-treated with melatonin, tryptamine, or 6-hydroxymelatonin (P<0.05), but not indole-3-carboxylic acid. Metabolic activity decreased after exposure to LPS/PepG and was maintained by melatonin and 6-hydroxymelatonin at the highest concentrations only. We have shown that in addition to melatonin, other structurally related indoleamine compounds have effects on NFκB activation and cytokine expression, GSH, mitochondrial membrane potential, and metabolic activity in endothelial cells cultured under conditions mimicking sepsis. Further work is needed to determine whether these compounds represent therapeutic approaches for disrupting the oxidative stress-inflammatory response signalling pathway in sepsis.
- 1 August 2011
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 107 (2) , 193-201
Melatonin and structurally similar compounds have differing effects on inflammation and mitochondrial function in endothelial cells under conditions mimicking sepsis
Development of organ dysfunction associated with sepsis is due in part to oxidative damage to mitochondria. Melatonin regulates the sleep-wake cycle and also has potent antioxidant activity. The aim of this study was to determine the effects of melatonin and other structurally related compounds on mitochondrial function, endogenous glutathione (GSH), and control of cytokine expression under conditions mimicking sepsis. Human endothelial cells were treated with lipopolysaccharide (LPS) plus peptidoglycan G (PepG) to simulate sepsis, in the presence of melatonin, 6-hydroxymelatonin, tryptamine, or indole-3-carboxylic acid. Nuclear factor κB (NFκB) activation, interleukin (IL)-6 and IL-8, total glutathione, mitochondrial membrane potential, and metabolic activity were measured. LPS and PepG treatment resulted in elevated IL-6 and IL-8 levels preceded by activation of NFκB (all P<0.0001). Treatment with all four compounds resulted in lower IL-6 and IL-8 levels, and lower NFκB activation (P<0.0001). Loss of mitochondrial membrane potential and endogenous glutathione was seen when cells were exposed to LPS/PepG, but these were maintained in cells co-treated with melatonin, tryptamine, or 6-hydroxymelatonin (P<0.05), but not indole-3-carboxylic acid. Metabolic activity decreased after exposure to LPS/PepG and was maintained by melatonin and 6-hydroxymelatonin at the highest concentrations only. We have shown that in addition to melatonin, other structurally related indoleamine compounds have effects on NFκB activation and cytokine expression, GSH, mitochondrial membrane potential, and metabolic activity in endothelial cells cultured under conditions mimicking sepsis. Further work is needed to determine whether these compounds represent therapeutic approaches for disrupting the oxidative stress-inflammatory response signalling pathway in sepsis.